A carregar...
Pharmacokinetics and Exposure-Response Analysis of RG7667, a Combination of Two Anticytomegalovirus Monoclonal Antibodies, in a Phase 2a Randomized Trial To Prevent Cytomegalovirus Infection in High-Risk Kidney Transplant Recipients
RG7667, a novel combination of two anticytomegalovirus (anti-CMV) monoclonal IgG1 antibodies (MCMV5322A and MCMV3068A), was designed to block CMV entry into host cells. It was developed as a potential therapy for preventing CMV infection and disease in transplant recipients. RG7667 was assessed for...
Na minha lista:
Publicado no: | Antimicrob Agents Chemother |
---|---|
Main Authors: | , , , , , , , |
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
American Society for Microbiology
2018
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5786805/ https://ncbi.nlm.nih.gov/pubmed/29133549 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01108-17 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|